Results 151 to 160 of about 4,521 (193)

P1017 Real-world effectiveness and safety of filgotinib with and without concomitant therapies in patients with Ulcerative Colitis: an interim analysis of the prospective, observational GALOCEAN study

Journal of Crohn's & Colitis
Filgotinib (FIL), a once-daily, oral Janus kinase 1 preferential inhibitor, was approved for the treatment of Ulcerative Colitis (UC) following the phase 2b/3, randomized SELECTION clinical trial.1 Real-world data on the effectiveness and safety of
M. Høivik MD- PhD, S. Vermeire, W. Reinisch, J. Seenan, M. Löwenberg, S. Schreiber, A. Armuzzi, E. Ricart, G. Doherty, R. Saldaña, W. Sawyer, C. Rudolph, A. Jus, C. Gilletta de Saint Joseph   +13 more
semanticscholar   +1 more source

P1160 Real-world comparative safety of filgotinib and upadacitinib for ulcerative colitis: a propensity score matching

Journal of Crohn's & Colitis
We previously reported that upadacitinib (UPA) demonstrated higher effectiveness than filgotinib (FIL) in the treatment of ulcerative colitis (UC) [1]. We aimed to compare safety profiles between FIL and UPA.
A. Nogami, K. Asonuma, S. Okabayashi, M. Ikenouchi, S. Shinzaki, M. Fukata, T. Kobayashi   +6 more
semanticscholar   +1 more source

P110 Baseline characteristics, disease activity, patient-reported outcomes and safety in patients with rheumatoid arthritis treated with filgotinib in the UK: up to 1-year interim results from FILOSOPHY

Rheumatology
FILOSOPHY (NCT04871919) is an ongoing, prospective, observational real-world European study of filgotinib for RA. We report up to 1-year interim data from UK patients.
Muhammad K. Nisar, Smita Bhat, O. Bouzid, Tariq Daud, Thomas P A Debray, James B Galloway, Neil D McKay, Lindsay Robertson, H. Tahir   +8 more
semanticscholar   +1 more source

Ulcerative colitis disease severity affects the speed of symptom relief under filgotinib treatment: a post hoc analysis of the phase 2b/3 SELECTION study.

Intestinal Research
Background/Aims Filgotinib is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). This study aimed to assess symptomatic response with filgotinib 200 mg (FIL200) according to disease severity ...
M. Saruta, S. Danese, Y. Takatori, T. Kaise, C. Rudolph, M. Ferrante, Toshifumi Hibi   +6 more
semanticscholar   +1 more source

In which patients with ulcerative colitis would filgotinib be effective?

Intestinal Research
Article: Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study (Intest Res 2025;23:65-75)
Jihye Park
semanticscholar   +1 more source

P1140 Filgotinib effectiveness and safety in moderate and severely active patients with Ulcerative Colitis: early real-world outcomes in an interim analysis of data from the prospective, observational GALOCEAN study

Journal of Crohn's & Colitis
A post hoc analysis of the SELECTION trial (NCT02914522) showed that patients with moderately active Ulcerative Colitis (UC) were more likely to respond to filgotinib (FIL), a once-daily, oral Janus kinase 1 preferential inhibitor, than those with ...
J. Seenan, M. Høivik, S. Vermeire, S. Schreiber, W. Reinisch, M. Löwenberg, G. Doherty, C. Gilletta de Saint Joseph, E. Ricart, R. Saldaña, W. Sawyer, O. Bouzid, C. Rudolph, A. Armuzzi   +13 more
semanticscholar   +1 more source

A Constant Filgotinib Delivery Adhesive Platform Based on Polyethylene Glycol (PEG) Hydrogel for Accelerating Wound Healing via Restoring Macrophage Mitochondrial Homeostasis.

Small
Skin wound healing is often hindered by disrupted mitochondrial homeostasis and imbalanced macrophage glucose metabolism, posing a critical challenge to improve patient outcomes.
Jian Xie, Yiqian Huang, Xiaofeng Hu, Xiaowei Wu, Xi Luo, Pengfei Wei, Wei Jing, Bo Zhao, Jiansheng Su   +8 more
semanticscholar   +1 more source

Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study

United European Gastroenterology journal
Background Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with ...
A. Nogami, K. Asonuma, Shinji Okabayashi, Maiko Ikenouchi, Takahisa Matsuda, S. Shinzaki, M. Fukata, Taku Kobayashi   +7 more
semanticscholar   +1 more source

Drug Interaction Potential of Berberine Hydrochloride When Co-Administered with Tofacitinib and Filgotinib in Rats

Drug Design, Development and Therapy
Propose The co-treatment of ulcerative colitis with berberine hydrochloride (BBR), the Janus kinase(JAK) inhibitor Tofacitinib (TOFA), and Fligotinib (FIGA) is feasible and sophisticated in terms of mechanism.
Jinglong Wang, Shijia Lu, Chenxiao Zhang, Junjie Wang, Huiru Wu, Guofei Li   +5 more
semanticscholar   +1 more source

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Indian Journal of Rheumatology
This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav   +3 more
semanticscholar   +1 more source